7-(4-Bromobutoxy)-3,4-dihydroquinolin-2(1H)-one
| Code | Size | Price |
|---|
| CDX-B0697-G001 | 1 g | £173.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
Short term storage:+20°C. Long term storage:+20°C.
Documents
Further Information
Alternate Names/Synonyms:
Aripiprazole Impurity
Appearance:
White to off-white powder.
CAS:
129722-34-5
EClass:
32160000
Form (Short):
solid
GHS Symbol:
GHS07
Handling Advice:
Protect from light and moisture.
Hazards:
H302, H315, H319, H332, H335
InChi:
InChI=1S/C13H16BrNO2/c14-7-1-2-8-17-11-5-3-10-4-6-13(16)15-12(10)9-11/h3,5,9H,1-2,4,6-8H2,(H,15,16)
InChiKey:
URHLNHVYMNBPEO-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 129722-34-5. Formula: C13H16BrNO2. MW: 298.18. Aripiprazole is an atypical antipsychotic. Aripiprazole is a partial agonist at dopamine D2 receptors, partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A, receptors. 7-(4-Bromobutoxy)-3,4-dihydroquinolin-2(1H)-one is an intermediate used for the synthesis of Aripirazole. This compound can be used as a reference compound for this impurity and potential degradation product.
MDL:
MFCD06658540
Molecular Formula:
C13H16BrNO2
Molecular Weight:
298.18
Package Type:
Vial
Precautions:
P261, P280, P305, P338, P351
Product Description:
Aripiprazole is an atypical antipsychotic. Aripiprazole is a partial agonist at dopamine D2 receptors, partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A, receptors. 7-(4-Bromobutoxy)-3,4-dihydroquinolin-2(1H)-one is an intermediate used for the synthesis of Aripirazole. This compound can be used as a reference compound for this impurity and potential degradation product.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
O=C(CC1)NC2=C1C=CC(OCCCCBr)=C2
Solubility Chemicals:
Soluble in chloroform or methanol.
Transportation:
Non-hazardous
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at RT.
References
(1) Y. Oshiro, et al.; J. Med. Chem. 41,658 (1998) | (2) H.-X. Ge, et al.; Arzneim.-Forsch./Drug Res. 56, 673 (2006) | (3) T. Poorna Chander, et al.; Synthet. Commun. 37, 4337 (2007) | (4) K.S.V. Srinivas, et al.; Chromatographia 68, 635 (2008)